Received Jun 27, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RAB | RABIES (RABAVERT) | NOVARTIS VACCINES AND DIAGNOSTICS | 1 | Unknown | IM |
The patient received first dose of RabAvert vaccine, it was due on day seven for the second dose but did not receive it; Case reference number US-BN-2025-000015 is a spontaneous case initially received from pharmacist via Med Communication (reference number: USBAV25-0032) on 06-Jan-2025 and concerns a male patient of unspecified age. The patient's medical history and concomitant medication details were not provided. On 30-Dec-2024, the patient received first dose of RabAvert vaccine (batch number: unknown) along with its constituent parts prefilled syringe, needle for injection and needle for reconstitution intramuscularly, at unknown dose, site of administration for indication pre-exposure for travel. As reported the patient did not receive the second dose of RabAvert vaccine on day seven (explicitly coded as 'inappropriate schedule of vaccine administered'). At the time of initial report, it was unknown if the patient experienced any adverse events due RabAvert. No further information was provided.; Reporter's Comments: A male patient of unspecified age received the first dose of RabAvert vaccine for indication pre-exposure for travel. As reported the patient did not receive the second dose of RabAvert vaccine on the day seven, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse events due RabAvert. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A male patient of unspecified age received the first dose of RabAvert vaccine for indication pre-exposure for travel. As reported the patient did not receive the second dose of RabAvert vaccine on the day seven, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse events due RabAvert. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: NONE